These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 19118495

  • 1. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.
    Sahin O, Fröhlich H, Löbke C, Korf U, Burmester S, Majety M, Mattern J, Schupp I, Chaouiya C, Thieffry D, Poustka A, Wiemann S, Beissbarth T, Arlt D.
    BMC Syst Biol; 2009 Jan 01; 3():1. PubMed ID: 19118495
    [Abstract] [Full Text] [Related]

  • 2. Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
    von der Heyde S, Bender C, Henjes F, Sonntag J, Korf U, Beißbarth T.
    BMC Syst Biol; 2014 Jun 25; 8():75. PubMed ID: 24970389
    [Abstract] [Full Text] [Related]

  • 3. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X, Wang S, Lee CK, Yang X, Liu B.
    Cancer Lett; 2011 Aug 01; 307(1):72-79. PubMed ID: 21497990
    [Abstract] [Full Text] [Related]

  • 4. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA, Vellon L, Lupu R.
    Ann Oncol; 2005 Aug 01; 16(8):1253-67. PubMed ID: 15870086
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells.
    Belkhiri A, Dar AA, Peng DF, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W.
    Clin Cancer Res; 2008 Jul 15; 14(14):4564-71. PubMed ID: 18579663
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.
    Zheng L, Tan W, Zhang J, Yuan D, Yang J, Liu H.
    Cancer Immunol Immunother; 2014 Jun 15; 63(6):581-6. PubMed ID: 24668364
    [Abstract] [Full Text] [Related]

  • 11. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.
    Breast Cancer Res Treat; 2010 Sep 15; 123(2):387-96. PubMed ID: 19946741
    [Abstract] [Full Text] [Related]

  • 12. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E, Arndt-Jovin DJ, Nagy P, Jovin TM, Szöllosi J, Vereb G.
    Cytometry A; 2005 Oct 15; 67(2):161-71. PubMed ID: 16163699
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.
    Breast Cancer Res Treat; 2010 Aug 15; 122(3):685-97. PubMed ID: 19859802
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R.
    Cytometry; 2001 Aug 01; 44(4):338-48. PubMed ID: 11500850
    [Abstract] [Full Text] [Related]

  • 18. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
    Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL.
    Clin Cancer Res; 2007 Aug 15; 13(16):4909-19. PubMed ID: 17699871
    [Abstract] [Full Text] [Related]

  • 19. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
    Schneider JW, Chang AY, Rocco TP.
    Semin Oncol; 2001 Oct 15; 28(5 Suppl 16):18-26. PubMed ID: 11706392
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.